Company: KROS
Filing Date: 2025-10-15
Form Type: 8-K
Source: 0001104659-25-099512
Chunk: 4

Company: Keros Therapeutics, Inc.
Filing Date: 2025-10-15
Form: 8-K
Item: Item 8.01
Chunk 4
---
Item 8.01 Other Events.

The information set forth
in the Introductory Note is incorporated by reference in this Item 8.01.

Additional Information
Regarding the Tender Offer

This communication is
for informational purposes only, is not a recommendation to buy or sell shares of the Common Stock and does not constitute an offer to
buy or the solicitation of an offer to sell shares of the Common Stock. The tender offer described in this communication has not yet commenced,
and there can be no assurances that the Company will commence the tender offer on the terms described in this communication or at all.
The tender offer will be made only pursuant to an offer to purchase, letter of transmittal and related materials that the Company expects
to distribute to its shareholders and file with the U. S. Securities and Exchange Commission (the “ Commission”) upon commencement
of the tender offer. STOCKHOLDERS AND INVESTORS SHOULD READ CAREFULLY THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED MATERIALS
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE VARIOUS TERMS OF, AND CONDITIONS TO, THE TENDER OFFER. Once the tender
offer is commenced, stockholders and investors will be able to obtain a free copy of the tender offer statement on Schedule TO, the offer
to purchase, letter of transmittal and other documents that the Company expects to file with the Commission at the Commission’s
website at www. sec. gov or by calling the Information Agent (to be identified at the time the offer is made) for the tender offer.

   3  

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this Current Report on
Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “continue,”
“expects,” “enable,” “intention,” “potential” and “will” or similar expressions
are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: the expected
closing of the Repurchase Transactions, the intended commencement of the tender offer; Keros’ expectations regarding its strategy,
progress and timing of its clinical trials for KER-065, including its regulatory plans; the therapeutic potential of KER-065, including
in patients with Duchenne muscular dystrophy; and Keros’ plan to distribute certain